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Monocarboxylate transporters (MCTs) constitute a family of 14
transmembrane proteins encoded by the SLC16A family of genes.
According to the transporter classiﬁcation system of Milton Saier
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. This is an open access article under(MCP) family (2.A.1.13), itself a member of the major facilitator super-
family (MFS). MCTs have been identiﬁed in all eukaryotic organisms
of which genomes have been sequenced to date. They can transport a
wide variety of substrates (Table 1). Four members of the MCT family,
MCT1, MCT2, MCT3 and MCT4 are monocarboxylate transporters re-
sponsible for the proton-linked transport of several monocarboxylate
metabolites, such as pyruvate, L-lactate and ketone bodies (acetoacetate
and D-β-hydroxybutyrate) across the plasma membrane [1,2]. Other
best characterized MCTs are MCT8 that has a high afﬁnity for thyroid
hormones T3 and T4, and MCT10/TAT1, a transporter of aromatic
amino acids [2,3]. MCT6 has been reported to facilitate the proton-
linked transport of bumetanide, but its natural substrate is unknown
[4]. MCT7 has been implicated in the export of ketone bodies by hepato-
cytes fueled with circulating fatty acids upon fasting [5]. Accordingly,
loss of MCT7 expression resulted in hepatic steatosis in Zebraﬁshes,
which was prevented by the introduction of human MCT7. MCT9 has
been clearly identiﬁed as a sodium- and pH-independent carnitine ef-
ﬂux transporter when it was expressed in Xenopus oocytes injected
with [3H]-carnitine [6]. The substrates and functions of the ﬁve other
MCT family members are currently unknown.
MCTs have numerous physiological functions as they are expressed
in a wide range of tissues (such as brain, skeletal muscle, heart, bowel
and liver) where they control, among others, the central metabolism of
glucose, gluconeogenesis, activation of T-lymphocytes, spermatogenesis,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
The MCT family of transporters.§
Human gene name Protein name Sequence accession ID Main substrates Tissue distribution
SLC16A1 MCT1 NM_003051 Lactate, pyruvate, ketone bodies Ubiquitous except β cells of the endocrine pancreas
SLC16A2 MCT8 NM_006517 T2, rT3, T3, T4 Ubiquitous
SLC16A3 MCT4 NM_004207 Lactate, ketone bodies Skeletal muscle, chondrocytes, leucocytes, testis, lung, brain,
ovary, placenta, heart
SLC16A4 MCT5 NM_004696 – Brain, muscle, liver, kidney, lung, ovary, placenta, heart
SLC16A5 MCT6 NM_004695 Bumetanide probenecid nateglinide Kidney, muscle, brain, heart, pancreas, prostate, lung, placenta
SLC16A6 MCT7 NM_004694 Ketone bodies Liver, brain, pancreas, muscle, prostate
SLC16A7 MCT2 NM_004731 Pyruvate, lactate, ketone bodies High expression in testis, moderate to low in spleen, heart, kidney,
pancreas, skeletal muscle, brain and leucocytes
SLC16A8 MCT3 NM_013356 Lactate Retinal pigment epithelium, choroid plexus
SLC16A9 MCT9 NM_194298 Carnitine Endometrium, testis, ovary, breast, brain, kidney, spleen, retina
SLC16A10 MCT10/TAT1 NM_018593 Aromatic amino acids, T3,T4 Kidney (basolateral), intestine, muscle, placenta, heart
SLC16A11 MCT11 NM_153357 – Skin, lung, ovary, breast, lung, pancreas, retinal pigment
epithelium, choroid plexus
SLC16A12 MCT12 NM_213606 – Kidney, retina, lung testis
SLC16A13 MCT13 NM_201566 – Breast, bone marrow stem cells
SLC16A14 MCT14 NM_152257 – Brain, heart, muscle, ovary, prostate, breast, lung, pancreas liver, spleen, thymus
§ Adapted from references [5,6,10].
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port. In addition to their implication in various physiological processes,
they play signiﬁcant roles in pathological situations as can be exempli-
ﬁed by the case of tumors. This review will summarize the current
knowledge pertaining to their functions in the brain, where their physi-
ological roles are starting to emerge in greater details, and in cancer,
which represents a pathology in which MCTs are clearly occupying an
important position.
2. General description of monocarboxylate transporters
2.1. The MCT family: structural and functional characteristics
2.1.1. Structure
Theoretical predictions and biochemical assays with MCT1 as a
model protein indicate that all the members of the MCT family share a
common topology. Hydropathy plots predict the presence of 12-
transmembrane (TM) helices with intracellular C- and N-termini, a
large cytosolic loop between TM helices 6 and 7, and two highly con-
served sequences in TM1 and TM5 [7]. A common feature shared with
MFS members is a better sequence conservation in TM regions com-
pared to loops and C-termini. To date, no crystallographic characteriza-
tion ofMCTs has been reported, but Halestrap et al. [7–9] have proposed
3D models based on molecular modeling, the structure of the E. coli
glycerol phosphate transporter GlpT, site-directed mutagenesis and
the binding sites for 4,4′-diisothiocyano-2,2′-stilbenedisulfonic acid
(DIDS), a MCT1 inhibitor. These models suggest that the structure of
MCT1 at the plasmamembranemay swing between two states: a closed
conformation where the substrate-binding site is cytosolic and an open
conformationwhere this site is extracellular (for a graphical representa-
tion, see Fig. 3 in reference [7]).
2.1.2. Mechanism of activity
The predicted open and closed conformations of MCTs and kinetic
analyses of proton-linked transport of lactate into erythrocytes are the
basis for the proposed translocation mechanism of lactic acid transport
by human MCT1 through the plasma membrane. MCT1 preferentially
facilitates the uptake of lactic acid and operates in an ordered process
that starts when a proton binds to K38 at the extracellular surface of
MCT1, providing a positive charge to the lysine [8,9,11]. Proton binding
is followed by the binding of one molecule of lactate to form an ionic
pair, which promotes a conformational change from closed to open
state. It follows that the proton is transferred to D302 and lactate to
R306 (both residues are localized at the inner surface of the channel),thus deprotonating K38, which induces the return to the closed confor-
mation and exposure of the D302/R306 site to the cytosol. The pair H+/
lac− is released into the cytoplasm. Another essential residue for MCT1
activity is F360, protruding into the channel of the transporter where it
controls substrate selectivity by steric hindrance. According to this
mechanism, the transport of lactic acid by MCT1 is passive and bidirec-
tional: import and export depend on the intra- and extracellular con-
centrations of lactate and protons [2,7]. This molecular model
highlights the importance of three residues, which are conserved in
the four members of the MCT family that transport monocarboxylates
(MCT1, MCT2, MCT3 and MCT4) and in MCT7, where there is a conser-
vative substitution of D302 by E302.
2.1.3. Substrates
MCT1, MCT2, MCT3 and MCT4 are responsible for the bidirectional
proton-linked transport of monocarboxylates across the plasma
membrane, and will be the focus of this review. These MCT isoforms
show preference for short chain monocarboxylates, including those
substituted on positions two and three, such as pyruvate, L-lactate, D-
β-hydroxybutyrate and acetoacetate. Quantitatively, lactate is one
of the most important metabolites for these transporters, with a
stereoselectivity for L- over D-lactate [7] consistent with the fundamen-
tal role of the L stereoisomer in eukaryotic cellmetabolism.With a Kmof
22–28 mM, MCT4 has the lowest afﬁnity for lactic acid [12] (Table 2).
However, it has a high turnover rate [13], making it particularly well
adapted for the export of lactate by glycolytic cells where it helps to
control intracellular pH homeostasis [12,14]. Comparatively, MCT1 has
an intermediate afﬁnity for lactate (Kmlactate = 3.5–10 mM) and is
widely expressed inhealthyand cancer tissues [2,15].MCT2(Kmlactate=
0.5–0.75 mM) and MCT3 (Kmlactate = 5–6 mM) show the highest afﬁn-
ity for lactate, but their expression is restricted to very speciﬁc tissues
(see Section 2.1.5) [16–18]. Differences in the Km of the transporters
for pyruvate are more pronounced, with Kmpyruvate values of 1.0, 0.1
and 153 mM for MCT1, MCT2 and MCT4, respectively [7]. MCT2 has
the highest afﬁnity for ketone bodies, with KmD-β-hydroxybutyrate =
1.2 mM and Kmacetoacetate = 0.8 mM determined in Xenopus oocytes
[19]. For MCT1, these values are KmD-β-hydroxybutyrate = 12.5 mM and
Kmacetoacetate = 5.5 mM [20]. The transport of ketone bodies by MCT3
has not been evaluated, and is not likely to occur through MCT4 due
to the very low afﬁnity of the transport for these substrates [7]. Beyond
natural substrates, recent evidence also shows that MCT1 is controlling
the uptake of 3-bromopyruvate [21] (an alkylating agent developed for
cancer therapy) and of dichloroacetate [22] (a pyruvate dehydrogenase
kinase inhibitor that restores themitochondrialmetabolism of pyruvate
Table 2
Km values of MCT1, MCT2, MCT3 and MCT4.
Transporter Kmlactate Kmpyruvate KmD-β-hydroxybutyrate Kmacetoacetate References
MCT1 3.5–10 mM 1.0 mM 12.5 mM 5.5 mM [2,7,15,20]
MCT2 0.5–0.75 mM 0.1 mM 1.2 mM 0.8 mM [7,16–19]
MCT3 5–6 mM – – – [16–18]
MCT4 22–28 mM 153 mM – – [7,12]
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several types of cancers).
Lactate is one of the main substrates of MCT1–4. This metabolite is
generated from pyruvate (produced from glycolysis and glutaminolysis)
during lactic fermentation. In most normal tissues where lactate is
produced,MCT1 is responsible for its export across theplasmamembrane
to the extracellular space [2,23]. However, in glycolytic cancer cells
and other speciﬁc tissues such as white muscle ﬁbers and astrocytes,
MCT4 predominates over MCT1 for lactate export (see details in
Sections 3.1 and 4.1) [15,24–26]. The low afﬁnity of MCT4 for pyruvate
could prevent the release of pyruvate that is essential for the conversion
of NADH into NAD+ for the maintenance of a high glycolytic ﬂux [2,23].
In metabolic pathways comprising lipogenesis, gluconeogenesis
and oxidative phosphorylation (OXPHOS), lactate can be used as a
substrate taken up from the extracellular space. Cells that consume
lactate may express MCT1, MCT2 or both depending on tissues and
species [2,27]. In many cancer cells with an oxidative metabolic ﬁn-
gerprint, MCT1 is the major MCT isoform to be expressed [2,25,28].
It promotes the import of lactate that then fuels the TCA cycle and
OXPHOS [25,29]. Accordingly, there is increasing evidence pointing
towards shuttling of this metabolite between cells with different
metabolic behaviors in a same tissue. Such phenomenon has been
described in the skeletal muscle where glycolytic/white ﬁbers export
lactate through MCT4 and oxidative/red ﬁbers express MCT1 to im-
port lactate to be used as a fuel for the TCA cycle [30,31]. A similar
mechanism has been proposed to account for a metabolic symbiosis
between glycolytic/hypoxic cancer cells and oxidative/oxygenated
cancer cells in tumors [25]. In the brain, glycolytic oligodendrocytes
and astrocytes export lactate through MCT1 and MCT4 to fuel oxida-
tive neurons expressing MCT2 [32–34]. The roles of MCTs in brain
physiology and in tumor pathology are detailed in Sections 3 and 4,
respectively.
2.1.4. Inhibitors
Several MCT inhibitors have been identiﬁed, but none are speciﬁc
for a given MCT isoform and most of them present a high afﬁnity for
other proteins (Table 3). Oldest described inhibitors are phloretin,
ﬂavonoids such as quercetin, stilbene disulphonates (including
DIDS and 4,4′-dibenzamidostilbene-2,2′-disulphonate [DBDS]), and
α-cyano-4-hydroxycinnamate (CHC) and its analogs [1,7]. All have
off-target effects. In particular, CHC has the capacity to inhibit theTable 3
Comparison of inhibitor selectivity for MCT1, MCT2 and MCT4.
Inhibitor Inhibition index MCT1 MCT2
Phloretin Ki (μM) 5 14
Quercetin % inhibition 89 83
DIDS Ki (μM) 434 –
DBDS % inhibition at 0.1 mM 0 56
NPPB Ki (μM) 9 –
CHC Ki (μM) 166 24
AR-C155858 Ki (nM) 1.2 (2.3)⁎ b10⁎$
AZD3965 Binding afﬁnity (nM) 1.6 9.6
7ACC2 IC50 for lactate uptake (nM) 11 –
Abbreviations: CHC, α-cyano-4-hydroxycinnamate; DBDS, 4,4′-dibenzamidostilbene-2,2′-disu
MCT, monocarboxylate transporter; NI, no inhibition; NPPB, 5-nitro-2-(3-phenylpropylamino)
⁎ Determined on rat MCT isoforms.
$ No signiﬁcant inhibitory effect when MCT2 is associated with embigin instead of basigin.mitochondrial pyruvate carrier (MPC, Ki ~ 2 μM), hence the mito-
chondrial uptake of pyruvate, much more efﬁciently than MCT1 (Ki
166 μM) [35]. Other inhibitors have been more recently developed
that exhibit a high afﬁnity for MCTs [36]. Compound AZD3965 is a
dual MCT1 and MCT2 inhibitor currently evaluated as an anticancer
agent in Phase I clinical trials for patients with prostate cancer, gas-
tric cancer or diffuse large B cell lymphoma (ClinicalTrials.gov
NCT01791595). Importantly, the related compound AR-C155858 is
a dual MCT1/2 inhibitor that inhibits MCT2 when it is bound to ancil-
lary protein basigin but not when it is bound to its preferred chaper-
one protein embigin [36] (see also Section 2.2.3). Draoui et al. [37,38]
have recently identiﬁed several original compounds belonging to
the 7-aminocarboxycoumarine family that potently inhibit MCTs.
Measurements of the inhibition of lactate ﬂux revealed that the
most active compounds (IC50 = 10–50 nM) are three log orders
more active than CHC. Interestingly, 7-(N-benzyl-N-methylamino)-
2-oxo-2H-chromene-3-carboxylic acid (7ACC2) was further reported
to be an inhibitor of lactate uptake (IC50 = 11 nM on 14C-lactate ﬂux
inhibition) that does not inhibit lactate export [38]. Subtle allosteric
regulation of MCT conformation was proposed to account for unidirec-
tional ﬂux inhibition. Another possibility that remains to be investigat-
ed would be an inhibitory effect on the MPC [35].
2.1.5. Cell-speciﬁc distribution
Information exists about the cellular distribution of MCT1–4
(Table 1), although it cannot be considered exhaustive. Expression of
MCT1 is viewed as being rather ubiquitous, since it is found in several
tissues andorgans. It is encountered in allmuscle cells, although it is par-
ticularly enriched in cells of oxidative (type I) ﬁbers [48–52]. In the
heart, it is found in cardiomyocytes [16,53,54]. In the liver, hepato-
cytes exhibit strong MCT1 expression [16,22,53,55]. Different levels
of MCT1 expression are found along the gastrointestinal tract in the
stomach, duodenum, jejunum, ileum, cecum, colon and rectum,
associated with epithelial cells (including enterocytes) on both
basolateral and apical membranes, suggesting that the transporter
is involved in both the absorption of monocarboxylates from the
lumen and their efﬂux towards blood [56–62]. In the blood, erythro-
cytes [53,63–65] and immune cells including lymphocytes and
monocytes [66] do express MCT1. The transporter is also present in
adipocytes of white adipose tissue [18,67]. In the placenta, MCT1
was found to be expressed in syncytiotrophoblasts in a polarizedMCT4 Other targets References
41 GLUT [14,19,39–41]
– Many [19,42]
NI Aquaporin, Cl−/HCO3− exchanger [14,39,43,44]
– [19,39]
240 [14,19,39]
991 Mitochondrial pyruvate carrier [14,19,35,39]
– [45,46]
– [47]
– [37,38]
lphonate; DIDS, 4,4′-diisothiocyanostilbene-2,2′-disulphonate; GLUT, glucose transporter;
-benzoate.
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69]. The transporter is also present in cells of exocrine glands, such as
sebaceous glands of the skin and mammary glands [70]. The cellular
distribution of MCT1 in the nervous system has been studied and de-
scribed in more details. MCT1 was found to be expressed in the brain
by endothelial cells [71–73], astrocytes [74–77], oligodendrocytes
[78,79] andmicroglial cells [80,81]. In addition, some subsets of neurons
express MCT1 [75,82,83], notably in speciﬁc brain areas such as the hy-
pothalamus [84,85]. Tanycytes, a glial cell type found in the hypothala-
mus, do also express MCT1 [86]. In the peripheral nervous system,
MCT1 was found in Schwann cells and dorsal root ganglia neurons
within the endoneurium [87,88], in addition to the epineurium [89].
MCT2 has a more restricted tissular and cellular distribution than
MCT1. It was ﬁrst described in liver hepatocytes and in the kidney in
collecting ducts [16]. MCT2 is also expressed by the spermatid tail in
the testis [16,90]. In the central nervous system, it was shown to be
the major neuronal MCT isoform [77,83,91]. Some data further suggest
that MCT2 could be expressed by endothelial cells delineating cerebral
blood vessels [73,92], by some rat astrocytes [76,93] and by tanycytes
in the hypothalamus [86].
MCT3 is expressed by only two cell populations in the entire
organism. It is found on retinal pigmented epithelial cells [94,95] as
well as on the choroid plexus epithelium [17].
MCT4 was shown to be expressed by a subset of muscle cells com-
posing glycolytic (type II) ﬁbers [49,50,96]. It is also present in some
types ofwhite blood cells, includingmacrophages [66,97,98]. In the cen-
tral nervous system, the transporter is found exclusively in astrocytes
[83,99], with the exception of tanycytes in the hypothalamus [86]. In
the peripheral nervous system, Schwann cells have been recently
found to express MCT4 [87].
2.1.6. Subcellular distribution
Since MCTs play an essential role in the exchange of metabolites be-
tween the cytoplasm and the extracellular environment, a great major-
ity of reports have described them to be localized at the subcellular level
on the plasma membrane of every cell type in which they were de-
scribed. There are, however, a few examples for which further details
about the subcellular distribution have been reported. In muscle cells,
both MCT1 and MCT4 were found to be associated with intracellular
structures such as triads, T tubules, sarcoplasmic reticulum and intracel-
lular membranes, but to a different degree for each transporter [52,96].
Similarly in neurons, which are highly polarized cells, a speciﬁc subcel-
lular distribution of MCT2 was evidenced and described: MCT2 expres-
sion is particularly enriched in dendritic spines, associated with the
postsynaptic density [91,100]. MCT2 was found not only to colocalize
with several postsynaptic density proteins (e.g. PSD95), but also to be
associatedwith a subset of proteins speciﬁcally enriched in the postsyn-
aptic density including PICK1 and GluR2/3, a subunit of α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors [101,
102]. Moreover, MCT2 was detected within spines in a vesicular-like
compartment [101,102], suggesting that it could undergo some trafﬁck-
ing between this intracellular compartment and the plasmamembrane.
Indeed, it was shown that neuronal stimulation with neuroactive sub-
stances such as glutamate (in the presence of glycine) or brain-
derived neurotrophic factor (BDNF) can induce the translocation of
the intracellular MCT2 pool to the plasma membrane and, thereby, en-
hance lactate uptake [102]. Likewise, in several types of cancers,
MCT2, MCT3 and MCT4 have been found to be expressed at the mem-
brane of intracellular substructures [103,104], which could indicate
intracellular trafﬁcking also in tumors.
In addition to its association with vesicle-like structures in neuronal
spines, MCT2 can also be found on the intracellular membrane of mito-
chondria in neurons [105,106]. Such an expression in mitochondria, in
association with the presence of the lactate dehydrogenase B (LDHB)
isoform,was proposed as an evidence for direct lactate oxidationwithin
mitochondria [105,107]. A similar observation was reported for MCT1in neurons [105] and in cardiac and skeletal muscle cells [108,109].
These observations, however, remain highly controversial, notably
due to the non-speciﬁc binding of antibodies and contamination of
mitochondrial membrane preparations, as extensively reviewed and
discussed previously [35].
2.2. Regulation
Most of the studies pertaining to MCT regulation focused on
MCT1, so most available information is related to this protein.
Known regulatory processes can be divided in 3 categories: tran-
scriptional, expressional and regulation through interactions with
proteins.
2.2.1. Transcriptional and epigenetic regulations
SLC16A1/MCT1 gene expression can be regulated in different ways
depending on cell and tissue types and on metabolic needs. In the skel-
etal muscle, increases in Ca2+ and AMP levels due to chronic stimula-
tion or exercise increase MCT1 transcription and promote the activity
of the Ca2+-dependent protein phosphatase calcineurin (CN) and of
AMP-activated protein kinase (AMPK) [110,111]. CN is responsible for
the dephosphorylation and activation of nuclear factor of activated T
cells (NFAT), a transcription factor that recognizes several NFAT-
binding consensus sequences on theMCT1 promoter [111]. In the skel-
etal muscle, inhibition of CN by cyclosporine A and FK506 induced a
phenotypic reshaping of red oxidative ﬁbers rich in MCT1 into white
slow oxidative ﬁbers with low MCT1 and higher MCT4 expression
[111,112]. In myocytes, cyclosporine A can further prevent hypertrophy
[112], a process related to upregulation of MCT1 [111]. Thus, although it
was not yet formally demonstrated, the control of the expression of
MCT1 in the exercising muscle probably depends on the binding of
NFAT to the gene promoter. When AMP levels rise, AMPK stimulates
PGC1α, a transcriptional coactivator that upregulates MCT1 expression
and promotes the formation of highly oxidative muscle ﬁbers [113]. Ac-
cordingly, exercise stimulation of rats resulted in a transient increase in
both MCT1 and MCT4 mRNA levels, with evidence for AMPK involve-
ment as an upstream intermediate [114,115]. In another report, howev-
er, direct AMPK activation by 5-aminoimidazole-4-carboxamide-1-β-D-
ribonucleoside (AICAR) has been shown to stimulate MCT1 promoter
activity in both L6 myoblasts and HepG2 hepatoma cells, but it signiﬁ-
cantly reduced the activity of the MCT4 promoter by more than 50%
[23]. AICAR has also been reported to decrease the activity of the
MCT1 promoter in Sertoli cells [116]. It has further been reported that
thyroid hormone T3 is able to increase the levels of MCT1 and MCT4
mRNAs, although in the skeletal muscle only MCT4 protein expression
increased [117]. In cancer, MCT1 expression has been found to be re-
pressed in human breast cancer cells through hypermethylation of
CpG islands in the promoter region of the gene [118]. Still in cancer,
MCT1 protein expression has also been reported to be regulated by hyp-
oxia in a p53-dependent manner [119]. A direct interaction between
p53 and the MCT1 gene promoter was proposed to decrease MCT1
mRNA stability.
MCT2 expression is mainly controlled posttranscriptionally, al-
though some authors have described that food deprivation can induce
the SLC16A7/MCT2mRNA expression in rat brain stem cells for the use
of ketone bodies as respiratory fuels [120]. In the brain, stimulation of
the PI3K-Akt–mTOR pathway by insulin, insulin-like growth factor 1
(IGF1) or noradrenaline induces a translational activation of MCT2 in a
way similar to the increment seen in cultured cortical murine neurons
treated with BDNF [121–123]. An epigenetic regulation of SLC16A7/
MCT2 was also evidenced in prostate cancer cells [124]. A selective de-
methylation of an internal promoter and a reciprocal hypermethylation
of anupstreampromoter region led to a switch inMCT2 isoform expres-
sion and a distinct regulation ofMCT2 translation.
The promoter activity of SLC16A3/MCT4 is stimulated by hypoxia fol-
lowing the binding of transcription factor hypoxia-inducible factor-1
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the transcription start [23,24]. Consequently, hypoxia increases MCT4
expression in several cell types, including cancer cells. An epigenetic
regulation of SLC16A3/MCT4 was also evidenced in clear cell renal cell
carcinoma [125]. Indeed, lower DNA methylation at speciﬁc CpG sites
resulted in higher MCT4 mRNA expression and correlated with worst
outcome for patients.
Information regarding other MCT isoforms is very limited, though
there is a study connecting MCT8 expression changes with develop-
ment and disease [3].
2.2.2. Expressional regulation
Mechanisms implicated in the regulation of MCTs have not been
deeply investigated, but some authors have pointed at the importance
of some speciﬁc sequences and secondary structures in the 5′ and 3′ un-
translated region (UTR) of MCTs mRNAs. In particular, the 3′ UTR of
MCT1 is much longer than the ones of MCT2 and MCT4, and it contains
a potential cytosolic polyadenylation element and hexanucleotide re-
peats [23]. These elements might be critical for polyadenylation at the
exit of the mitotic phase during cell cycle and for the regulation of initi-
ation factor eIF4E, which could be linked with the increase in MCT1 ex-
pression observed at protein but not mRNA level [23,111]. In addition,
MCT1 bears in its C-terminus a LL motif and two acidic clusters of
amino acids that could be involved in protein targeting [111], for exam-
ple in the translocation of the protein to the sarcolemma in cisternae
close to the t-tubules in cardiomyocytes [126]. Sequence analysis sug-
gests that MCTs are not targets for posttranslational modiﬁcations
such as glycosylation, and to date no evidence of other posttranslational
modiﬁcations has been reported.
2.2.3. Regulatory proteins
The correct expression, localization and activity of MCTs depend on
interactions with ancillary proteins, primarily basigin/CD147 and
embigin/gp70 [8,127,128]. These proteins are anchored to the plasma
membrane through a single transmembrane domain containing a con-
served glutamate residue. They also possess a short intracellular C-
terminus and a large glycosylated extracellular domain with two or
three immunoglobulin domains depending on the splice variant [129].
In addition to its chaperone role, basigin presents a huge variety of li-
gands, such as cyclophilins and integrins, taking part in several func-
tions including the induction of metalloproteinases, spermatogenesis
and responsiveness to lymphocytes [130].
Several groups have demonstrated with different techniques (e.g.
immunoﬂuorescence, co-immunoprecipitation, cross-linking and ﬂuo-
rescence resonance energy transfer) the crucial role of ancillary proteins
for MCTs to be localized and active at the plasma membrane [36,128,
131–133]. In their absence, MCTs are not able to reach their ﬁnal posi-
tion and accumulate in the Golgi apparatus [128,132]. Basigin is more
widely expressed in tissues than embigin, and appears more frequently
as the preferential partner for MCT1, MCT3 and MCT4, whereas MCT2
preferentially interacts with embigin [36,128]. Experiments of site-
directed mutagenesis have further revealed that the transmembrane
domain of the ancillary protein lies adjacent to TM3 and TM6 of MCTs
[8,36] and that disruption of the interaction between MCT1 and basigin
by organomercurial p-chloromercuribenzene sulphonate (pCMBS) in-
duces inhibition of MCT1 activity [128]. Besides MCT1–4, the necessity
of the other members of the MCT family to interact with ancillary pro-
teins remains unclear. MCT8 does not require such interaction for its
correct plasma membrane localization and activity [134].
Other proteins have been suggested to bind to MCTs. The receptor
for hyaluronic acid CD44 can interact with MCT1 and MCT4 in lung
and prostate cancer cells [103]. Carbonic anhydrase II (CAII, a cytosolic
CA isoform) and CAIV (an extracellular CA isoform) can also establish
interactions with MCT/basigin complexes via MCTs on the cytosolic
side and basigin on the extracellular side, enhancing the activity of the
transporters [135,136]. Increased MCT activity by CAs could be due toa processwhereby CAs supplyMCTswith protons, or to faster transport.
Nonetheless, improved MCT activity was also seen with catalytically
inactive CAs [135,136], a phenomenon that is still incompletely under-
stood. MCT1 has also been reported to colocalize with LDH in the mito-
chondria of L6 rat skeletal muscle cells and to co-immunoprecipitate in
themitochondrial fraction of theprotein extract in absence of detergent,
suggesting a weak interaction between both proteins at least at the mi-
tochondrial level in these cells [137]. The authors proposed a model of
“intracellular lactate shuttle/lactate mitochondrial oxidation complex”
in which lactate would be reduced in pyruvate by LDH and further
imported into the mitochondrial stroma by MCT1 for further oxidation.
Because LDHB and LDHA have different afﬁnities for lactate and
pyruvate and as MCT isoforms have different Km and Vmax values
depending on their substrate, potential interactions of LDHs with
MCTs could represent a mechanism to ﬁne-tune monocarboxylate
transport orientation across membranes. As mentioned earlier, howev-
er, the concept of intracellular lactate shuttle and lactate mitochondrial
oxidation is highly disputed for several reasons [35]. Finally, in neurons,
MCT2 binds to the AMPA receptor subunit GluR2, of which it controls
the plasma membrane localization [102,138]. Moreover, it was shown
that two adhesionmolecules, the neuroplastins, can also serve as acces-
sory proteins for MCT2 in the central nervous system and regulate its
exposure at the cell surface [139].
3. MCTs in the central nervous system
3.1. MCTs and the astrocyte-neuron lactate shuttle
The cellular distribution of MCTs in the central nervous system
associated with the distribution of other essential metabolic compo-
nents (such as the LDH isoenzymes [140,141]) has suggested a key
role of these carriers in the shuttling of energy metabolites between
brain cells. Indeed, the expression of MCT4 on astrocytes that produce
large amounts of lactate and the expression of MCT2 on neurons using
lactate as an efﬁcient oxidative energy substrate have contributed to
the emergence and establishment of the “astrocyte-neuron lactate
shuttle” concept [32,141–143] (Fig. 1).
Glutamate uptake by astrocytes via thehigh afﬁnity, Na+-dependent
glutamate transporters GLAST and GLT1 was initially reported to cause
a rise in intracellular Na+ that would activate the Na+/K+ ATPase
[144–147]. As a consequence, glucose uptake would be enhanced and
would result in a greater lactate production and release [148,149].
Both MCT1 and MCT4 can convey lactate release by astrocytes: MCT1
appears to be involved in basal lactate release, whereas MCT4 would
be required for enhanced lactate export [150,151]. In addition to gluta-
mate, K+ can also enhance glycolysis in neurons [152–154]. Moreover,
it was recently demonstrated that NH4+ constitutes a signal released
by neurons that favors lactate release by astrocytes, most likely via
MCTs [155]. Lactate constitutes not only a suitable oxidative energy
substrate for neurons, but it can even be preferred over glucose both
in vitro and in vivo [156–161]. The expression of MCT2 by neurons,
together with LDHB, provides an ideal condition for lactate uptake and
utilization as an energy substrate by these cells. It has further been
shown that the level of MCT2 expression at the plasma membrane of
these cells can be modulated by speciﬁc neuroactive substances,
including BDNF, via a translocationmechanism allowing for a rapid reg-
ulation and control of energy substrate supply [162]. In addition, MCT2
expression can also be regulated at the translational level in cultured
cortical neurons by various neuroactive substances including BDNF, in-
sulin, IGF-1 and noradrenaline [121–123,162]. Such a relatively rapid
mechanism to enhanceMCT2 expression occurs at the level of neuronal
processes and does not require the cell body, suggesting a synapse-
speciﬁc regulation [123]. A similar enhancement of MCT2 expression,
together with the synaptic proteins PSD95 and the AMPA receptor
subunit GluR2, was demonstrated in mice in vivo after injection of
BDNF into the hippocampus [163].
Fig. 1.Model depicting MCT-mediated lactate exchanges between astrocytes and neurons in the brain. In the model, astrocytes, depicted on the left, have a high glycolytic metabolism.
They import glucose via glucose transporters (GLUT) and then sequentially convert glucose to pyruvate and ATP using glycolysis, and pyruvate to lactate using lactate dehydrogenase
A (LDHA). Lactate is exported together with protons via MCT4. Neurons, depicted on the right, import lactate and protons via MCT2. Lactate is oxidized to pyruvate by lactate
dehydrogenase B (LDHB) and pyruvate fuels the TCA cycle to support ATP production through oxidative phosphorylation.
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Asmentioned in Section 3.1, the neuronal expression ofMCT2 is reg-
ulated in parallel with other proteins that are also regulated in a
synapse-speciﬁc manner (such as PSD95), whereas MCT2 is even asso-
ciated physically with GluR2, a speciﬁc subunit of AMPA receptors with
which it undergoes trafﬁcking either by being inserted together into the
plasma membrane or being internalized from the plasma membrane
into the endosomal system [102,138]. Moreover, MCT2 expression
in vivo is regulated by the same mechanism that activates some imme-
diate early genes, i.e., Arc and Zif268, known to be involved in synaptic
plasticity [163]. These observations strongly suggest that MCT2 plays a
key role in the supply of energy substrates to neurons in order to sustain
changes involved in synaptic plasticity. Indeed, Alberini et al. [164] have
shown that downregulating the expression of not only MCT2 (the neu-
ronal transporter) but also of the two glial transportersMCT1 andMCT4
in the rat hippocampus prevented learning and memory. Remarkably,
while exogenously supplied lactate could overcome the deﬁcit when ei-
ther of the glial transporters, MCT1 or MCT4, were downregulated, it
was not the case forMCT2, further demonstrating the importance of lac-
tate release from astrocytes and its use by neurons via MCT-mediated
transfer. These results were conﬁrmed in a different learning task
involving spatial memory [165]. Interestingly, exposure of neurons to
lactate can lead to the modiﬁcation of N-methyl-D-aspartate (NMDA)
receptor-mediated currents and to enhancement of plasticity gene
expression [166]. These effects require the presence of neuronal MCTs.
Lactate indeed acts by modifying the level of intracellular NADH
(which requires lactate to be metabolized intracellularly) and, thus,
the redox state of the cell.3.3. MCTs in brain diseases
3.3.1. Neurodegenerative diseases
Considering the important emerging roles of MCTs in metabolic in-
teractions between the different brain cell types, it is not surprising to
discover that alterations of MCT expression are implicated in a variety
of diseases involving the central or the peripheral nervous systems. It
is speciﬁcally the case for neurodegenerative diseases. Thus, together
with the discovery that oligodendrocytes express MCT1 and are in-
volved in a lactate shuttle to provide energetic support to axons [33,
167], it was also shown that a reduction of MCT1 expression in a trans-
genic mouse model leads to axonal degeneration, notably in the spinal
cord [79]. A similar reduction of MCT1 expression was evidenced in
the spinal cord of amyotrophic lateral sclerosis patients [79]. Similarly,in parallel with the ﬁnding that MCT1 and MCT4 are expressed by
Schwann cells, a reduction of the expression of MCT1 in cultured cells
was reported to alter myelination [87], which was associated with a
delay of regeneration following nerve crush in a transgenic mouse
model [88]. Accordingly, in brain tissues of multiple sclerosis patients,
astrocytes exhibit enhanced MCT1 expression, whereas demyelinated
axons have lower MCT2 expression in inactive lesions [81].
In a rat model of Alzheimer's disease where rat received bilateral
intrahippocampal injections of the Aβ25–35 fragment, MCT2 expres-
sion was reduced in parallel with decreased lactate content and cogni-
tive deﬁcits in spatial learning and memory, as assessed by the Morris
Water Maze test [168]. In contrast, no alteration of the expression and
localization of MCT1 and MCT2 was found in the substantia nigra and
striatum of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
mouse model of Parkinson's disease [169].
3.3.2. Epilepsy
Epilepsy represents a condition for which several studies have re-
ported changes in the expression and/or localization of the different
MCTs in the brain. In the human epileptogenic hippocampus, MCT1
expression is decreased in microvessels [170], whereas MCT2 is
redistributed from astrocytic end-feet to plasmamembranes facing syn-
apses [171]. In an immature and an adult lithium-pilocarpine rat model
of epilepsy, MCT1 mRNA was found to be commonly enhanced, but
more in the adult during the acute phase of status epilepticus [172].
MCT2 mRNA increased mainly in adults within the circuit of seizures.
In three other rat models of epilepsy, one using the drug methionine
sulfoximine and two using episodes of perforant path stimulation,
MCT1 expression was reduced in microvessels, whereas it was en-
hanced in astrocytes of the hippocampus [173]. The expression of
MCT4 was also investigated in patients with temporal lobe epilepsy
and in a pilocarpine rat model of temporal lobe epilepsy. A decrease in
MCT4 expression was detected in the cortex of temporal lobe epilepsy
patients, and a similar decrease was observed in the pilocarpine rat
model 12 to 14 h after drug administration [174]. The reduction of the
abundance of MCT4 (which is essentially an astrocytic transporter)
was linked to a parallel reduction of the glial glutamate transporter
excitatory amino acid transporter 1 (EAAT1), an observation that
could explain neuronal hyperexcitability and epileptogenesis.
3.3.3. Brain ischemia
Changes in MCT expression have been reported following brain is-
chemia. In a transient global rat ischemia model, intense MCT1 labeling
was found in CA1 pyramidal neurons, astrocytes, endothelial cells and
ependymocytes [175]. An increase in the expression of MCT1 and
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mia induced by compression in rats [80]. In addition, modulation of
MCT4 expression by hypoxia, as demonstrated in cultured astrocytes
[151], could provide a mechanism by which neuronal death can be
preserved under ischemic conditions [176] and could be exploited as a
neuroprotective strategy in intermittent hypoxia preconditioning-
induced epileptic tolerance [177].
3.3.4. Metabolic diseases
A distinct class of pathologies in which modulation of brain MCT
expression could play a role is represented by certain metabolic dis-
eases. Indeed, repeated hypoglycemia was reported to have an impact
onMCT expression in various brain regions. This is the case in the hypo-
thalamus, an important region for nutrient sensing and metabolic ho-
meostasis. Thus, an injection of insulin to induce an hypoglycemic
episode altered MCT2 expression of the vagal complex in opposite di-
rection between male rats and estrogen-treated oviarectomized female
rats [178]. Recurrent insulin-induced hypoglycemia enhancedMCT2ex-
pression in the dorsal vagus complex,whereas acute hypoglycemia sup-
pressed MCT2 expression in the ventromedial hypothalamus [179].
Conversely, catecholaminergic A2 neurons in the dorsal vagal complex
exhibited reducedMCT2 expression following insulin-induced hypogly-
cemia [180].
In contrast to hypoglycemia, hyperglycemia was found to enhance
MCT1 expression globally in the brain, most likely in endothelial cells
and astrocytes [181], while having no effect on MCT1, MCT2 and
MCT4 expression in the medio-basal hypothalamus [182]. Exposure of
mice to a high fat, high sugar diet for several weeks induced the cortical
expression of MCT1, MCT2 and MCT4 that occurred preferentially in
neurons throughout the cortex [183].
While these data suggest the possible involvement of MCTs in met-
abolic homeostasis and its possible dysregulations, clear evidence was
provided by the phenotypical characterization of haploinsufﬁcient
MCT1 transgenic mice [184]. These mice were shown to resist to the
development of diet-induced obesity and its associated metabolic
dysfunctions, including insulin resistance and hepatic steatosis. Inter-
estingly, under a high fat, high sugar diet, haploinsufﬁcient MCT1 mice
had reduced food intake, suggesting that MCTs could be key factors im-
plicated in nutrient sensing and subsequent food intake regulation and,
eventually, dysregulation. This would certainly constitute an interesting
topic for future investigation.
4. MCTs in cancer
4.1. Expression of MCTs in different cancer types
MCT1 and MCT4 are the most widely MCT isoforms expressed in
cancer cells. MCT1 expression has been reported in a variety of human
cancers including head and neck, breast, lung, stomach, colon, bladder,
prostate and cervix cancers, as well as gliomas [25,26,185–188]. MCT1
has also been proposed to be the most important isoform responsible
for lactate transport across the plasmamembrane in breast cancer, blad-
der cancer, non-small cell lung carcinomas (NSCLC) and ovarian carci-
nomas [103,188]. MCT4 is also widely distributed in different cancer
types. Its expression has indeed been reported in breast, colon, bladder,
and prostate cancers, as well as in cancers of the gynecologic tract and
gliomas [103,186–188]. Despite a low expression at the plasma mem-
brane, MCT4 is further present intracellularly in NSCLC [104]. Compara-
tively to MCT1 and MCT4, MCT2 and MCT3 have been less studied in
cancer. MCT2 has been found in the cytoplasm of breast carcinoma,
NSCLC, colon adenocarcinoma and ovarian adenocarcinoma cancer
cells [103,104], and MCT3 has also been reported to be expressed intra-
cellularly in cancer and stromal cells of NSCLC [104]. With respect to
MCT2 andMCT4, some authors have postulated that a high intracellular
expression could reﬂect the localization of these transporters on themembranes of intracellular vesicles or organelles where they could
potentially transport lactate and/or pyruvate [26,188].
The expression of the chaperon proteins of MCTs in cancer cells is an
important factor to take into account because they behave as key medi-
ators in oncogenesis. CD147 and CD44 have been associated to MCT1
and MCT4 in different tumor types. MCT1 and CD147 expression have
been signiﬁcantly correlated in bladder [188] and ovarian cancers
[103], and CD44 was reported to be associated with MCT1 expression
in lung cancer [103]. CD147-MCT1 double-positive bladder tumors
showed poor prognosis and unfavorable clinical pathological parame-
ters [188]. In addition, experimentally induced CD147 downregulation
increased the chemosensitivity of bladder cancer cell lines to cisplatin
chemotherapy [188]. MCT4 expression has also been correlated to
CD147 expression in prostate, breast and lung cancers [103,188]. Re-
cently, Pertega-Gomes and Baltazar [189] further reported a correlation
between the expression of MCT1, MCT2 and MCT4 and the different
stages of prostate cancer progression.MCT1was present in both normal
epithelium and malignant glands, MCT2 was expressed from benign to
prostate intraepithelial neoplasia lesions and in malignant glands, and
MCT4 was expressed only in malignant glands associated to poor prog-
nosis. Therefore, the authors proposed thatMCT1 andMCT2would play
a role in tumor maintenance, whereas MCT4 would increase tumor
aggressiveness. MCT2 was also proposed as an interesting biomarker
for prostate cancer [189]. In another study in NSCLC [104], Eilertsen
et al. proposed MCT1 as a biomarker for prognostic and survival. The
co-expression of GLUT1 and MCT1 and of GLUT1 and MCT4 was found
as a negative prognostic factor associated with poor disease-speciﬁc
survival.
4.2. MCTs in the metabolic relationships between glycolytic and oxidative
cancer cells
From a metabolic standpoint, established tumors contain different
types of cancer cells. Oxidative cancer cells can use different metabolic
substrates to fuel OXPHOS, including glucose, glutamine, lipids and lac-
tate [15]. Glycolytic cancer cells result from environmental selection
(e.g. by hypoxia) or from metabolic adaptation in order to sustain bio-
synthesis for proliferation (the ‘Warburg effect’) [190–194]. The switch
from an oxidative to a glycolytic metabolism formally corresponds to
unframing glycolysis from the TCA cycle and OXPHOS in order for
glycolysis to preferentially fuel lactic fermentation. The conversion of
glycolytic end-products pyruvate, NADH and H+ into lactate and
NAD+ indeed serves to regenerate the NAD+ pool necessary to main-
tain glycolysis at a high rate [195]. In the glycolytic compartment of tu-
mors, metabolism accounts for elevated lactate production and for an
extracellular lactate accumulation up to concentrations that can reach
10 to 40mM [196]. These high levels of lactate have been shown to cor-
relate with tumor aggressiveness and poor prognosis in several types of
human cancers [15,196–202]. MCTs play an essential role in the meta-
bolic homeostasis of the tumor microenvironment: they ensure the
maintenance of glycolytic and acid-resistant phenotypes [15,203], thus
contributing to the malignant behavior of cancer cells. MCTs allow gly-
colysis to operate at high speed by facilitating lactate export, and they
are also involved in pH regulation by the co-transport of protons.
Lactate is not a metabolic dead-end product of glycolysis but is
rather a tumor growth-promoting factor. In a striking similarity with
brain metabolism, lactate can be used as a metabolic substrate by a va-
riety of oxidative cancer cells. Lactate can indeed generally fuel the oxi-
dative metabolism of oxygenated cancer cells [25,29]. According to the
‘metabolic symbiosis’ hypothesis initially proposed by Sonveaux et al.
in cancer [25], lactate produced by glycolytic cancer cells that rely on
glucose as a main fuel is imported by oxidative cancer cells that use lac-
tate in mitochondrial metabolism as a main fuel compared to glucose,
thus sparing glucose for glycolytic cancer cells [204,205] (Fig. 2). Indeed,
this concept seems to also apply for brain tumors (gliomas) inwhich the
occurrence of an intercellular lactate shuttle akin to the one normally
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cellular metabolic interactions to sustain the survival and growth of
the tumor [206]. MCT4, which has a low afﬁnity for lactate but a high
turnover rate, is particularly well adapted to facilitate lactate export
by glycolytic cancer cells [12,13]. Its expression is up-regulated by
hypoxia:when theO2 supply is compromised, cancer cells activate tran-
scription factor HIF-1, of which MCT4 is a target gene [24]. MCT4 also
shows a higher Km for pyruvate compared to lactate, which prevents
the efﬂux of pyruvate that would be detrimental for the maintenance
of a high glycolytic ﬂux. Conversely, MCT1 has a high afﬁnity for lactate
and is preferentially expressed in oxidative cancer cells that take up lac-
tate [25,207]. The use of pharmacological inhibitors and RNA interfer-
ence experiments have revealed that MCT1 is the main transporter
responsible for lactate uptake by these cells [25,119,207,208]. Inside
oxidative cancer cells, lactate reacts with NAD+ to yield pyruvate,
NADH and H+ (the LDHB reaction), and both pyruvate and NADH can
fuel the TCA cycle and OXPHOS in mitochondria, which depends on
the malate–aspartate shuttle for the mitochondrial import of NADH
[29].
In addition to its function as a metabolic substrate, lactate can also
act as a signaling agent in oxidative cancer cells. In two seminal papers
[209,210], Lu et al. initially showed that lactate can behave is a hypoxia
mimetic factor capable of activating transcription factor HIF-1 in
normoxic cancer cells. In the process, lactate must be taken up by
cancer cells through a MCT1-facilitated process, oxidized to pyruvate
by LDHB, and pyruvate competes with 2-oxoglutarate to inhibit
the prolylhydroxylases (PHDs) of HIF-1 [207,209,210] (Fig. 3), i.e.,
oxygen- and 2-oxoglutarate-dependent enzymes that catalyze the hy-
droxylation of HIF-1 subunit α on two proline residues to initiate the
proteasome-dependent degradation pathway of HIF-1α [211]. Thus,
by interfering with the normal degradation pathway of HIF-1α, lactate
can trigger HIF-1 activity independently of hypoxia in oxidative cancer
cells. An established consequence of such signaling is an increased tran-
scription and release of vascular endothelial growth factor (VEGF) by
oxidative cancer cells, which can stimulate endothelial cells to initiate
and angiogenic response [194,207] (Fig. 3, see also Section 4.3). Because
MCTs are equilibrative lactate/H+ transporters and glycolytic cancer
cells produce large amounts of lactate and protons, these cells cannot
abundantly take up exogenous lactate and, therefore, do not activate
HIF-1 upon exposure to lower levels of exogenous lactate [195,207].
MCTs also promote migration and invasion processes in cancer.
Izumi et al. [212] ﬁrst showed that MCT1 and MCT4 expressionFig. 2.Model depicting a metabolic symbiosis based on the exchange of lactate between glyco
import glucose via glucose transporters (GLUT) and then sequentially convert glucose to py
(LDHA). Lactate is exported together with protons via MCT4. Oxidative cancer cells, depicte
lactate dehydrogenase B (LDHB) generating NADH as a byproduct, and both pyruvate and NADcorrelates with invasion in human lung cancer cells. In agreement
with their ﬁndings, others further showed that the MCT inhibitor CHC
decreases the migration and invasion of glioma cells [187]. Moreover,
in conditions of glucose deprivation, MCT1-CD147 complexes were
found to be stabilized andMCT1 actively promoted themigration of ox-
idative SiHa and HeLa human cervix cancer cells towards glucose
through a mechanism that was blocked using speciﬁc shRNAs targeting
MCT1, or CHC to inhibit MCT1 activity [208]. However, whether and
how MCT1 could function as a glucose sensor is still unknown.
4.3. MCTs in the crosstalk between cancer and endothelial cells
Endothelial cells are responsive to lactate stimulation in a way that
promotes tumor progression. Indeed, similar to oxidative cancer cells,
endothelial cells can take up lactate in a MCT1-facilitated process, al-
though, contrary to oxidative cancer cells, they donot efﬁciently use lac-
tate as a fuel [213]. In normoxic endothelial cells, lactate was found to
stimulate HIF-1 activity in a manner similar to what was described for
oxidative cancer cells, i.e., by sequentially serving as a precursor of pyru-
vate, inhibiting HIF PHDs, stabilizing HIF-1α and activating HIF-1 [213]
(Fig. 3). However, the ﬁnal proangiogenic effectors identiﬁed are
different. Indeed, in endothelial cells, lactate did not stimulate VEGF
production but rather increased the production of basic ﬁbroblast
growth factor (bFGF) and the expression of the prototypical VEGF re-
ceptor VEGFR2. Taking into account the fact that lactate can stimulate
VEGF production independently of hypoxia in cancer cells [207,209,
210], both paracrineVEGF signaling and autocrine bFGF signaling on en-
dothelial cells could thus account for the proangiogenic effects of lactate
in tumors.
Independently of HIF-1, lactate has also been show to sequentially
activate NF-κB, trigger proangiogenic IL-8 production and activate the
IL-8 pathway in an autocrine manner in endothelial cells [214,215]
(Fig. 3). This pathway shares with the lactate-HIF-1 pathway MCT1-
facilitated lactate uptake, lactate oxidation to pyruvate (the LDHB reac-
tion) and pyruvate-mediated PHD inhibition. PHD inhibition then res-
cues inhibitor of NF-κB kinase β (Iκκβ) from degradation, resulting in
inhibition of inhibitor of NF-kB α (IκBα). NF-κB activation was found
to further mandatorily require NADH, the byproduct of the LDHB reac-
tion, to be available to sequentially fuel NAD(P)H oxidases, trigger the
production of reactive oxygen species (ROS), and fully inactivate IκBα
[214]. Accordingly, the mitochondrial use of NADH by oxidative cancer
cells but not by endothelial cells that are more glycolytic explains whylytic and oxidative cancer cells. In the model, glycolytic cancer cells, depicted on the left,
ruvate and ATP using glycolysis, and pyruvate to lactate using lactate dehydrogenase A
d on the right, import lactate and protons via MCT1. Lactate is oxidized to pyruvate by
H fuel the TCA cycle to support ATP production through oxidative phosphorylation.
Fig. 3.Model depicting proangiogenic lactate signaling in cancer. In the model, glycolytic cancer cells, depicted on the left, import glucose via glucose transporters (GLUT) and then
sequentially convert glucose to pyruvate and ATP using glycolysis, and pyruvate to lactate using lactate dehydrogenase A (LDHA). Lactate is exported together with protons viaMCT4.
MCT1 is expressed in endothelial cells and in oxidative cancer cells, depicted on the left, and catalyzes the uptake of lactate together with protons. In these cells, lactate is oxidized to
pyruvate by LDHB, producing NADH as a byproduct. Pyruvate inhibits prolylhydroxylases (PHDs). In endothelial cells, PHD inhibition stabilizes hypoxia-inducible factor (HIF-1)
subunit α, triggering HIF-1 activation and the transcriptional upregulation of vascular endothelial growth factor receptor 2 (VEGFR2). HIF-1 also indirectly increases bFGF, which is
secreted and activates the proangiogenic bFGF receptor (bFGFR). PHD inhibition further stabilizes inhibitor of NF-κB kinase β (Iκκβ), an inhibitor of inhibitor of NF-kB α (IκBα). NADH
aliments NAD(P)H oxidases (Nox) that produce reactive oxygen species (ROS) to further inhibit IκBα. Consequently, transcription factor NF-κB is activated and upregulates IL-8,
which is secreted and activates the proangiogenic IL-8 receptor (IL-8R). Oxidative cancer cells share with endothelial cells the lactate-HIF-1 pathway, but not the lactate-NF-κB
pathway. HIF-1 activation by lactate in these cells transcriptionally upregulates VEGF, which upon secretion can activate proangiogenic VEGFR2 in endothelial cells. Lactate signaling as
a whole can thus trigger angiogenesis independently of hypoxia.
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but not in oxidative cancer cells [29].
The proangiogenic properties of lactate andMCT1 are also supported
by observations in ischemic wound healing. Indeed, chronic lactate de-
livery to the wound site from a poly-D,L-lactide-co-glycolide polymer
was shown to accelerate revascularization, hence wound healing
[216]. Conversely, pharmacological inhibition of MCT1 by CHC blocked
reparative angiogenesis and the healing activity of lactate.
4.4. MCTs in the crosstalk between cancer and stromal cells
Over the past decades, studies on cancermetabolism highlighted the
importance of the interaction between cancer cells and their microenvi-
ronment, and particular attention has beenpaid to interactions between
cancer cells and ﬁbroblasts. Lisanti et al. [217] proposed the existence of
a metabolic relationship between stromal ﬁbroblasts and oxidativeepithelial cancer cells involvingMCTs, which they coined ‘ReverseWar-
burg Effect’. In this process, oxidative cancer cells induce an oxidative
stress in ﬁbroblasts that triggers a glycolytic switch, MCT4 expression
and the secretion of lactate, pyruvate and ketone bodies (Fig. 4). These
metabolites are then imported in a MCT1-dependent manner and
used oxidatively by the cancer cells. Experimentally, co-culturing breast
cancer cells with normal ﬁbroblasts upregulated MCT4 expression in
the ﬁbroblasts, which was prevented by the use of anti-oxidants such
as N-acetyl-L-cysteine [218]. The co-culture also stimulated MCT1
expression in the cancer cells. In another experiment, HaCaT
human epithelial keratinocytes were co-cultured with ﬁbroblasts,
resulting in MCT4 induction in the ﬁbroblasts [219]. Mechanistically,
ROS production following activation of the RAS oncogene and tran-
scription factor NF-kB in cancer cells was reported to be responsible
for metabolic reprogramming and enhanced MCT4 expression in
ﬁbroblasts [219].
Fig. 4.Model depicting metabolic commensalism of oxidative cancer cells for stromal cells. In the model, oxidative cancer cells, depicted on the right, produce reactive oxygen species
(ROS) that promote glycolysis and MCT4 expression in stromal cells. Glycolytic stromal cells, depicted on the left, import glucose via glucose transporters (GLUT) and then sequentially
convert glucose to pyruvate and ATP using glycolysis, and pyruvate to lactate using lactate dehydrogenase A (LDHA). They also produce ketone bodies. Lactate and ketone bodies are
exported together with protons via MCT4. Oxidative cancer cells import lactate, ketone bodies and protons via MCT1. Lactate is oxidized to pyruvate by lactate dehydrogenase B
(LDHB) generating NADH as a byproduct, and both pyruvate and NADH fuel the TCA cycle to support ATP production through oxidative phosphorylation. Ketone bodies can also be
catabolized.
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abolic commensalism whereby oxidative cancer cells exploit the meta-
bolic activities of stromal cells. In biopsies of humanbreast cancer,MCT1
expressionwas found to predominate in epithelial cancer cells, whereas
stromal cells preferential expressed MCT4 [218]. Tissue analysis of
positive lymph nodes revealed ampliﬁed mitochondrial mass and me-
tabolism in metastatic breast cancer cells and a lack of detectable mito-
chondria togetherwith highMCT4 expression in stromal cells, including
cancer-associated ﬁbroblasts (CAFs), adipocytes and inﬂammatory cells
[220]. Frozen sections of primary tumors were further screened for
functional mitochondria. Analyses showed higher expression and activ-
ity of succinate dehydrogenase and cytochrome C oxidase, as well as
higher levels of NADH, in epithelial cancer cells compared to adjacent
stromal cells, thus convincingly indicating strong OXPHOS activity in
the cancer cells [221]. High MCT4 expression in the stromal tissue has
been proposed to have an important prognostic role in breast cancer,
which could improve the prognostic value of other biomarkers: stromal
MCT4 expression is normally inversely correlated to the expression of
caveolin-1, and the combination of the two markers could be helpful
to identify intermediate risk groups [222,223].
In human head and neck cancer, MCT1 expression was reported to
be associated to cancer cells [224]. Cancer-associated ﬁbroblasts
(CAFs) had high MCT4 expression.
In human prostate cancer, MCT1 was present in cancer cells and
MCT4 in CAFs [189]. CAFs also had high CAIX expression, suggesting a
glycolytic metabolism. Interestingly, the concomitant presence of ele-
vated levels of MCT4 in CAFs and MCT1 in cancer cells was related to a
poor clinical outcome [189]. An independent study conﬁrmedMCT1 ex-
pression in prostate cancer cells [225], but it was associated to a strong
cytoplasmic reactivity for LDHA, whichwould indicate a glycolytic rath-
er than an oxidative metabolism of the cancer cells. In the same study,
MCT1 was found in CAFs and tumor-associated myoblasts, with LDHB
upregulation (compared to cancer cells) indicative of an oxidative me-
tabolism of the stroma in 40% of cases. Similar ﬁndings have been
made in lung cancer, with, comparatively, MCT1 and LDHA overexpres-
sion in cancer cells and no MCT but LDHB expression in CAFs [226].
Collectively, these data support the general existence of MCT-
dependent relationships between cancer cells and stromal cells that
could encompass metabolic commensalism of cancer cells for stromal
cells but also the opposite situationwhere stromal cells wouldmetabol-
ically use lactate and other monocarboxylates exported by cancer cells.4.5. MCTs in the crosstalk between cancer and immune cells
Cancer cells and immune cells interact in a broad range of manners.
As recently reviewed byHirt et al. [227], the in vitro study of those inter-
actions in 3D models replicates better in vivo observations than stan-
dard 2D co-cultures. Among protumoral immune inﬂuences on cancer
cells, a well-known observation is that chronic inﬂammation can pro-
mote oncogenesis, as illustrated for example by the higher incidence
of colorectal cancer in inﬂammatory bowel disease patients. With re-
spect to metabolism, various studies point the high intratumoral lactic
acid concentration as a unifying mechanism of the immunosuppressive
effects of cancer cells [228].
Using monocyte-derived dendritic cells (DC), Puig-Kroger et al.
[229] ﬁrst observed that lactate can decrease the DNA binding activity
NF-κB in a dose-dependent manner, thus impairing DC maturation.
They also showed that TNFα release was decreased, although this oc-
curred only at higher lactate concentrations (40 mM), i.e., the highest
dose of lactate that can be found in human tumors. Nasi et al. [230]
analyzed thedefect of DCdifferentiation in dense cell cultures, and iden-
tiﬁed lactic acid as being responsible for this. In their experiments, DC
induced to differentiate in high density cultures developed an anti-
inﬂammatory phenotype (with IL-10 production) and displayed a
preserved osteoclast differentiation potential, whereas low density
cultures resulted in IL-12- and TNFα-producing cells capable tomigrate
towards lymphoid tissue chemokine. While acidic pH alone had no ef-
fect and lactate alone had only a weak effect, lactic acid reproduced
the effects of high density culture, underlying the potential role of
MCTs in DC differentiation [230].
Activated T cells depend on glycolysis for energy production and
therefore need to release lactate, which depends on MCT1 in these
cells [231–233] (Fig. 5). In tumors, they are in competition with cancer
cells for nutrients, which, in addition to low pH, promotes T cell anergy
[227]. In this context, Fischer et al. [234] observed that lactic acid in-
hibits the proliferation of human cytolytic T lymphocytes (CTLs) in a
dose-dependent manner. Neither sodium lactate, lactic acid in a
solution buffered at pH 7.4 nor acidiﬁcation alone had antiproliferative
effects, indicating a speciﬁc activity of lactic acid. Upon lactic acid treat-
ment, CTLs showed decreased IL-12 and IFN-γ production and a lower
cytotoxic activity linked to a decrease in granzyme and perforin B con-
tent [234]. Because lactic acid blocked the release of lactate by CTLs
and pharmacological MCT1 inhibition had a similar antiproliferative
Fig. 5.Model showing the immunosuppressive activity of lactic acid on T cells. In the model, glycolytic cells, depicted on the left, import glucose via glucose transporters (GLUT) and then
sequentially convert glucose to pyruvate and ATP using glycolysis, and pyruvate to lactate using lactate dehydrogenase A (LDHA). Lactate is exported together with protons viaMCT4.
Activated T lymphocytes, depicted on the right, also depend on a glycolytic metabolism and must release lactate and protons, which in these cells is facilitated by MCT1. MCT1,
however, is a passive transporter that is antagonized by the high microenvironmental levels of lactic acid that can be found in glycolytic tissues.
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likely depends on lactate efﬂux inhibition [234] (Fig. 5). Consistently,
others independently showed that CTL stimulation in a lactic acidosis
medium, without prior exposure to lactic acid, decreased IFN-γ, TNFα
and IL-12 production, a response that was concentration-dependent
[235]. While cytokine production was completely inhibited at 20 mM
of lactic acid, exocytosis of lytic granules was reduced by only 50% at
this concentration, and CTL viability was not affected. This rapid effect
of lactic acid is concordant with the fast uptake of lactate. The differen-
tial manifestation of the two types of responses was explained by a
rapid inhibition of the MAPK-p38-JNK pathway by lactic acid, whereas
ERK and Akt pathways were preserved [235]. In these assays, similar
to what had been observed by Fischer et al., lactate alone or acidic pH
alone did not recapitulate the effects of lactic acid.
Lactate is also involved in tumor immune escape. In vivo, knocking-
down LDHA in cancer cells (and thus decreasing their glycolytic rate and
lactate secretion) resulted in natural killer (NK) cell activation, reduced
accumulation of myeloid-derived suppressor cells (MDSCs), reduced
immunosuppressive activity and smaller tumor sizes [236]. Direct ef-
fects of lactate were demonstrated by the same authors in vitro, by
showing that lactate, per se, decreases NK cell activity and increases
the differentiation of peripheral blood mononuclear cells to MDSCs
and their immunosuppressive activity. In vivo, a ketogenic diet, used
as a surrogate of LDHA knock-down, improved antitumor immunity, al-
though to a lesser extent [236]. Regulatory T cells and MDSCs were less
present than with a normal diet, and the number of immune effector
cells was increased.
In tumors, myeloid cells may polarize into M1 tumor-suppressive
macrophages or into M2 tumor-associated macrophages that secrete
proliferation- and survival-stimulating cytokines and proangiogenic
factors. Lactate can inﬂuence this process. Colegio et al. [237] indeed
showed that lactate can activate HIF-1 inmacrophages, driving their po-
larization to the M2 phenotype with a high VEGF secretion that would
promote tumor angiogenesis. Importantly, lactate needed the presence
of free protons to exert its effect, but an acidic pH alone was not sufﬁ-
cient to stabilize HIF-1α and activate HIF-1.When HIF-1αwas silenced,
the effects of lactate were absent.
5. Conclusions
MCTs represent the major path for inward and outward monocar-
boxylate ﬂuxes from cells and are key regulators of intracellular and
extracellular pH.
The description of the cell-speciﬁc distribution of MCT1–4 has con-
tributed to the emergence of the physiological concept of intercellularlactate shuttle [238,239]. First described in muscles by George Brooks
[240], this concept has seen its scope enlarged by its description in
other organs and tissues like the testis [90,241]. In the brain, thedebated
but now largely supported establishment of the ‘astrocyte-neuron
lactate shuttle’ concept is also expanding by the description of similar
lactate exchanges taking place between oligodendrocytes and axons
[34,167], as well as between Schwann cells and peripheral nerves [87].
Considering the importance of such a mechanism of metabolic cooper-
ation between cells under physiological activity, it may come as no sur-
prise that under pathological conditions such as cancer, a similar
mechanism operates or is used for the beneﬁt of cancer cells. Cancer
cells being opportunistic, they have developed strategies to survive in
their environment, and the expression of appropriate MCTs contribute
to their adaptation to many situations, as described in Section 4 by
many examples.
In the brain, the type of metabolic cooperation between cells is less
opportunistic but more homeostatic. It is for the functional beneﬁt of
the organ that these metabolic exchanges have developed, and they
rely on subtle equilibria. Any imbalances may lead on the long run to
deleterious consequences. Indeed, there is more and more evidence
thatmetabolic dysfunctions underlie neurodegenerative diseases rather
than being mere consequences [242]. Thus, it has been proposed in
many instances that bolstering neuroenergetics (including the capacity
of brain cells to produce and/or utilizemonocarboxylates, which also in-
clude ketone bodies) might be a good neuroprotective strategy [243,
244]. This possibility remains to be fully tested, but we lack for the mo-
ment a proper strategy to be able to enhance these aspects of energy
metabolism. This is why we need to gather more information about
the mechanisms regulating the expression of MCTs in the various
brain cell types. A better characterization of these mechanisms might
provide the necessary insights to develop an appropriate therapeutic
approach based on this knowledge.
Due to their important activities and their general overexpression in
cancers compared to healthy tissues, MCTs are interesting targets for
cancer therapy. In tumors, MCT1 gates lactate uptake by oxidative can-
cer cells and by endothelial cells, thus simultaneously controlling the
cataplerotic (Figs. 2 and3), proangiogenic (Fig. 4) and pro-migratory ac-
tivities of lactate. Consequently, MCT1 inhibition can have antimetabol-
ic, anti-angiogenic and anti-migratory effects that repress tumor growth
[25,119,207,213,214] and, potentially, progression to the metastatic
state [208]. In fact, in vitroMCT1 inhibition has been found to decrease
intracellular pH [25], elicit cell death [25,245] and decrease cancer cell
migration [208]. MCT4 also represents an interesting anticancer target,
as can notably be illustrated by the fact that MCT4 inhibition by siRNAs
reduced the migration of breast cancer cells [246].
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going task.While historical inhibitors are poorly selective forMCTs, CHC
in particular has been the focus of a vast number of in vitro and in vivo
studies showing its therapeutic effects [26]. However, this compound
has several drawbacks. It is poorly speciﬁc for a given MCT isoform
and can also inhibit the mitochondrial pyruvate carrier and anion ex-
changer 1 [26]. Moreover, it is usually described to be active in the
upper micromolar range. More recently, AR-C155858, a highly potent
MCT1/2 inhibitor, and AZD3965, a second-generationMCT1/2 inhibitor,
have been disclosed by AstraZeneca [46,233]. AZD3695 is currently in
Phase I/II clinical trials for advanced solid tumors and diffused B cell
lymphomas [247]. However, these molecules present a limited thera-
peutic action due to the compensatory effect of MCT4, which they do
not inhibit [248]. A new family of inhibitors, of which 7ACC2 is the lead-
ing compound, has been recently disclosed and described to selectively
inhibit lactate uptake (versus export) by cancer cells expressing both
MCT1 and MCT4 [37,38]. The future in vivo evaluation of these com-
pounds will provide key information about their therapeutic activity
and suitability for clinical evaluation.
Important issues still remain to be addressed for the clinical exploi-
tation of MCT inhibitors. First, the physiological role of these trans-
porters is still poorly characterized in many tissues. Systematic
characterization could beneﬁt from the generation of tissue-speciﬁc
MCT-deﬁcient mice that would further potentially reveal so far unsus-
pected toxicities linked to MCT inhibition. Second, little is currently
known about the regulation of MCT expression and activity. A better
characterization of endogenous and exogenous factors, including con-
ventional therapies, capable of inﬂuencing MCTs could eventually
allow to identify efﬁcient treatment combinations. Interestingly, MCTs
can transport anticancer agents 3-bromopyruvate, dichloroacetate and
iodoacetate across cancer cell membranes [26]. The study of MCT sub-
strates that can act as anticancer compounds is an interesting new
ﬁeld that should be further explored. Finally, the preclinical and clinical
development of MCT inhibitors would beneﬁt from the identiﬁcation
and validation of biomarkers ofMCT activity that would allow to predict
and to document a therapeutic response.
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